Cross-resistance to Tumour Promoters in Cancer Cell Lines
Author Information
Author(s): K. Nishio, Y. Sugimoto, K. Nakagawa, S. Niimi, Y. Fujiwara, M. Bungo, K. Kasahara, H. Fujiki, N. Saijo
Primary Institution: National Cancer Centre Research Institute, Tokyo, Japan
Hypothesis
The study investigates the growth inhibitory effects of tumour promoters on human cancer cell lines resistant to adriamycin or cisplatin.
Conclusion
The study suggests that drug-resistant cancer cell lines exhibit cross-resistance to both TPA-type and non-TPA-type tumour promoters, indicating a common mechanism of resistance.
Supporting Evidence
- K562/ADM cells showed 8.4-fold resistance to adriamycin compared to K562.
- PC-9/CDDP cells were 4.2-fold resistant to cisplatin compared to PC-9.
- TPA and okadaic acid inhibited the growth of K562 and PC-9 in a dose-dependent manner.
- K562/ADM and PC-9/CDDP cells exhibited cross-resistance to TPA-type and non-TPA-type tumour promoters.
- Accumulation studies showed no difference in drug uptake between sensitive and resistant cell lines.
Takeaway
Some cancer cells that are resistant to certain drugs also don't respond to specific tumour promoters, which helps scientists understand how drug resistance works.
Methodology
The study used the MTT assay to examine the growth inhibitory effects of various tumour promoters on human leukaemia and lung cancer cell lines.
Limitations
The study did not perform histological evaluations and focused primarily on in vitro assays.
Participant Demographics
The study involved human cancer cell lines derived from patients with leukaemia and lung cancer.
Want to read the original?
Access the complete publication on the publisher's website